# Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction

Study · id `cardio:ct-nct05881382` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05881382](<https://clinicaltrials.gov/study/NCT05881382>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05881382

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 4100 participants.

## Technical summary

Registry record NCT05881382. Randomized; quadruple masking; primary purpose treatment. Start 2023-09 (anticipated); primary completion 2025-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 4100 participants (planned count; ClinicalTrials.gov record NCT05881382, source copy `cardio:ctgov-nct05881382-2023-06-05`, retrieved 2026-10-26)
- Planned start: 2023-09 (anticipated) (ClinicalTrials.gov record NCT05881382, source copy `cardio:ctgov-nct05881382-2023-06-05`, retrieved 2026-10-26)
- Primary completion: 2025-09 (anticipated) (ClinicalTrials.gov record NCT05881382, source copy `cardio:ctgov-nct05881382-2023-06-05`, retrieved 2026-10-26)
- Completion: 2025-09 (anticipated) (ClinicalTrials.gov record NCT05881382, source copy `cardio:ctgov-nct05881382-2023-06-05`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05881382-2023-06-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
- Acronym: HEAL-MI
- Condition: ST Elevation Myocardial Infarction
- Intervention (Drug): Dutogliptin + Filgrastim
- Intervention (Drug): Placebo
- Lead sponsor: Recardio, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)

## Provenance

Content hash: d523572d151d34bea4b58e9657ac2cc42749e20d74560663f3559084c9211f0b
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
